A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer

@article{Hussain2004API,
  title={A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer},
  author={Syed Anwer Hussain and Deborah D. Stocken and Peter L. Riley and Daniel H. Palmer and David Peake and Ju Ian Geh and D. F. Spooner and Nicholas James},
  journal={British Journal of Cancer},
  year={2004},
  volume={91},
  pages={844 - 849}
}
A randomised phase III trial of MVAC (methotrexate, vincristine, doxorubicin, cisplatin) vs gemcitabine and cisplatin (GC) (G 1000 mg m−2 days 1, 8, and 15 plus C 70 mg m−2 day 2, q 4 wks) indicated GC had similar efficacy and lower toxicity (JCO 2000). Significant haematologic toxicities in the GC arm occurred on day 15, necessitating dose adjustments in… CONTINUE READING